The secondary endpoints were changes from baseline in polyneuropathy stage, PND score, NIS, compound autonomic dysfunction test, Norfolk QoL-DN, troponin, NT-proBNP, interventricular septum thickness, and BMI. This evidence concerns the gene NPPB and polyneuropathy.